Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rani Therapeutics Holdings (RANI) Shares Outstanding (Weighted Average) (2020 - 2026)

Rani Therapeutics Holdings' Shares Outstanding (Weighted Average) history spans 7 years, with the latest figure at $180.0 million for Q1 2026.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 438.27% to $180.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $180.0 million, a 438.27% increase, with the full-year FY2025 number at $131.6 million, up 172255.59% from a year prior.
  • Shares Outstanding (Weighted Average) came in at $180.0 million for Q1 2026, up from $131.6 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $13.2 billion in Q2 2025, with the low at $23817.0 in Q4 2022.
  • Historically, Shares Outstanding (Weighted Average) has averaged $809.9 million across 5 years, with a median of $25.6 million in 2023.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): crashed 54.35% in 2022 and later surged 172255.59% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $23817.0 in 2022, then grew by 7.09% to $25505.0 in 2023, then skyrocketed by 199.3% to $76336.0 in 2024, then skyrocketed by 172255.59% to $131.6 million in 2025, then skyrocketed by 36.81% to $180.0 million in 2026.
  • Business Quant data shows Shares Outstanding (Weighted Average) for RANI at $180.0 million in Q1 2026, $131.6 million in Q4 2025, and $38.9 million in Q3 2025.